Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Type 2 Inflammation Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IL25 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL25 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View IL25 Products |
| Gene Delivery | IL25 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View IL25 Products |
| Benchmark Ab | Anti-IL25 Benchmark Antibody Recombinant positive control. |
View IL25 Products |
| Validator | IL25 siRNA Set For knockdown verification. |
View IL25 Products |
| Related Target A | IL17RA Co-receptor for IL-25 signaling |
View IL17RA Products |
| Related Target B | IL17RB Primary receptor for IL-25 |
View IL17RB Products |
| Related Target C | TSLP Synergistic alarmin in Type 2 immunity |
View TSLP Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse eval | Human/Mouse/Cyno ortholog proteins available with >95% purity |
| Receptor complex binding validation | High-purity IL17RA and IL17RB proteins for SPR/BLI assays |
| Lack of Controls | Clinical Benchmark Antibodies included |
| False Positives | Validated siRNA included for specificity checks |
Live IL25 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL25 therapeutics is intensifying, with major players shifting focus from traditional mAbs to bispecifics targeting multiple alarmins. As first-generation therapies reach the clinic, the next wave of R&D is targeting broad-spectrum Type 2 inflammation control in asthma and atopic dermatitis.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Various Biopharma | Asthma, Atopic Dermatitis | Receptor Blocking Assay (Need high-purity IL25 and IL17RB) |
| Bispecific Antibody | Emerging Biotechs | Severe Th2 Diseases | Heterodimer Validation (Need Cross-reactive Abs & TSLP/IL33) |
| Receptor Antagonist | Roche/Genentech (Historical) | Autoimmune / Allergy | Selectivity Assay (Need IL17 family panel) |